Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
The Company’s portfolio of Phase 3 product candidates are:
- Remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD) in children
- Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection
- REVASCOR® for advanced chronic heart failure
- MPC-06-ID for chronic low back pain due to degenerative disc disease
The Company also has a promising emerging pipeline and next generation technologies.
Innovative technology platform
Mesoblast’s novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.
Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes. Another key feature of Mesoblast’s cells is they can be administered to patients without the need for donor–recipient matching or recipient immune suppression.
Events
January 11, 2021 CEO
Presentation at H.C. Wainwright BioConnect 2021 Conference
December 18, 2020
Mesoblast Update on COVID-19 ARDS Trial
December 15, 2020
Mesoblast Phase 3 Chronic Heart Failure Results
Latest News
12 January 2021
CHF Phase 3 Trial Results Presented at Investor Conference >
12 January 2021
Mesoblast Healthcare Conference Investor Presentation >
11 January 2021
Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF >
18 December 2020
Mesoblast Webcast >
18 December 2020
Mesoblast Update on COVID-19 ARDS Trial >